Sun Pharma-Organon deal: How a $12-billion merger will reshape India’s pharma landscape

Sun Pharmaceutical Industries is making its boldest bet yet. The acquisition of Organon will nearly double Sun Pharma’s size — from a $6 billion to a $12 billion revenue company — creating one of the largest pharmaceutical players globally. In an exclusive interview with ET Now, Sun Pharma’s MD Kirti Ganorkar and CFO Jayashree Satagopan outlined why the timing is right, how integration will work, and where the growth will come from.

Why now, despite geopolitical uncertainty

Critics have questioned the timing of the deal given global geopolitical headwinds. Ganorkar was direct in his response. There is never a perfect moment for a transformational acquisition, he argued, and the strategic logic of the deal outweighs the short-term noise. The combined entity will gain the ability to commercialise a significantly larger product portfolio across global markets — an opportunity that cannot be indefinitely deferred.

Three growth engines at Organon

Organon’s business is structured across three segments, each with a distinct growth opportunity for the combined company.

The first is women’s health, an innovative, largely branded portfolio operating in a global market estimated at $30–35 billion, growing at 5–7% annually. Ganorkar noted that over 100 pipeline products are currently under development in this space, giving Sun Pharma ample room to in-license and commercialise new assets.

The second is biosimilars, currently growing at 13% and set to accelerate further. Ganorkar pointed to a landmark opportunity: biologics worth approximately $320 billion are set to go off-patent by 2035. Even if just 20% of that converts to biosimilars, it translates to a $60–70 billion market. Organon’s existing global platform — ranked seventh worldwide in biosimilars — gives Sun Pharma an immediate commercial foothold it would have taken years to build independently.

The third is established brands, which make up around 50% of Organon’s business and are currently flat. Sun Pharma plans to inject growth here through line extensions, new formulations, and combination products — a strategy the company has successfully executed before.

Innovative portfolio gets a boost

The combined company’s share of innovative drug revenues will rise from Sun Pharma’s current 20% to 27%. Key focus areas include dermatology, where Organon’s Vtama adds to Sun’s existing Ilumya franchise, as well as ophthalmology and women’s health in-licensing. Several Organon pipeline products are also expected to launch within two to three years of the deal closing.

Integration: Sun has done this before

The integration of a company that doubles your size is a legitimate concern. Satagopan acknowledged this plainly but pointed to Sun Pharma’s track record with Taro and Ranbaxy — two complex acquisitions that were successfully absorbed. The company plans to establish a dedicated integration office immediately, with a timeline running up to the deal’s expected closing in approximately nine months. Key focus areas will include talent assessment, market-by-market opportunity mapping, and cross-cultural alignment.

Debt is manageable, with a clear repayment plan

Organon carries significant debt, which Sun Pharma will refinance. The combined entity’s net debt-to-EBITDA ratio at the time of closing is expected to be around 2.3x — within normal range for a transaction of this scale, according to Satagopan. The two companies together generate roughly $2.5 billion in annual operating cash flow, which will fund both debt servicing and business investment. Satagopan was clear that Sun’s long-standing financial discipline remains intact, and the goal is to return to a net cash-positive position over time.

Margin profile: No deterioration expected

A key investor concern is margin dilution. Satagopan addressed this directly, noting that Organon’s adjusted EBITDA margins are actually slightly higher than Sun Pharma’s current 30%-plus levels. With cost synergies and operational efficiencies being built into the integration plan, the combined entity’s margins are expected to remain healthy.